Get the Stockscreener App
1.62
0.62%
0.01
Lava Therapeutics Nv stock is traded at $1.62, with a volume of 122.59K.
It is up +0.62% in the last 24 hours and up +1.89% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.61
Open:
$1.62
24h Volume:
122.59K
Relative Volume:
0.35
Market Cap:
$42.61M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
-1.5388
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
+9.46%
1M Performance:
+1.89%
6M Performance:
+17.39%
1Y Performance:
-19.00%
1-Day Range:
$1.60
$1.63
1-Week Range:
$1.44
$1.64
52-Week Range:
$0.8502
$2.06
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.62 | 38.67M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.36 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.56 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.81 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
811.97 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
309.94 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Advanced analytics toolkit walkthrough for LAVA Therapeutics N.V.July 2025 Gainers & Long-Term Safe Investment Ideas - newser.com
Can LAVA Therapeutics N.V. hit a new high this monthJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
How LAVA Therapeutics N.V. stock valuations compare to rivalsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
How LAVA Therapeutics N.V. (4PKB) stock expands through international marketsQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Insider Selling: LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Sells $1,460,000.00 in Stock - Defense World
Analyzing LAVA Therapeutics N.V. with risk reward ratio chartsMarket Growth Report & Breakout Confirmation Trade Signals - newser.com
Heatmap analysis for LAVA Therapeutics N.V. and competitorsTrade Analysis Summary & Free High Return Stock Watch Alerts - newser.com
What indicators show strength in LAVA Therapeutics N.V.Quarterly Trade Review & Capital Efficient Trading Techniques - newser.com
What analysts say about LAVA Therapeutics NV 4PKB stockCandlestick Trading Patterns & Minimal Investment Profits - earlytimes.in
What drives LAVA Therapeutics NV stock priceEmerging Market Stocks & Zero-Cost Stock Research by Professionals - earlytimes.in
Reversal indicators forming on LAVA Therapeutics N.V. stockEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Is LAVA Therapeutics N.V. forming a reversal patternJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com
Price momentum metrics for LAVA Therapeutics N.V. explainedEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Historical volatility pattern of LAVA Therapeutics N.V. visualizedMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
LAVA Therapeutics N.V. stock prediction for this weekMarket Rally & Verified Short-Term Plans - newser.com
Published on: 2025-10-21 15:08:21 - newser.com
Custom strategy builders for tracking LAVA Therapeutics N.V.2025 Biggest Moves & Step-by-Step Swing Trade Plans - newser.com
Gilde healthcare sells LAVA Therapeutics (LVTX) shares for $4.2m By Investing.com - Investing.com UK
Gilde healthcare sells LAVA Therapeutics (LVTX) shares for $4.2m - Investing.com India
[Form 4] LAVA Therapeutics NV Insider Trading Activity - Stock Titan
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement - Morningstar
LAVA Therapeutics N.V. recovery potential after sell offTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Analyzing net buyer seller activity in LAVA Therapeutics N.V.Weekly Profit Analysis & Stepwise Entry and Exit Trade Signals - newser.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lava Therapeutics Nv Stock (LVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 16 '25 |
Sale |
1.49 |
690,239 |
1,028,456 |
4,128,912 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 14 '25 |
Sale |
1.51 |
227,341 |
343,285 |
5,019,151 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 13 '25 |
Sale |
1.54 |
47,686 |
73,436 |
5,246,492 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 10 '25 |
Sale |
1.55 |
49,869 |
77,297 |
5,294,178 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
0.99%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):